Status:
COMPLETED
Study Evaluating MOA-728 in Subjects on Stable Methadone Maintenance
Lead Sponsor:
Bausch Health Americas, Inc.
Conditions:
Methadone-maintenance Subjects
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
This is a study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MOA-728 in subjects on stable methadone maintenance.
Eligibility Criteria
Inclusion
- History of methadone treatment for at least 1 month before day -1 at a dose of ≥ 30 mg/day, and a positive drug test result for methadone.
- Healthy as determined by the investigator on the basis of screening evaluations.
Exclusion
- Allergy to opioids (eg, codeine, morphine, or oxymorphone) or opioid antagonists (eg, naloxone or naltrexone).
- Any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease.
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
End Date :
May 1 2007
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00447811
Start Date
March 1 2007
End Date
May 1 2007
Last Update
November 25 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Willingboro, New Jersey, United States, 08046